Summary
Nine of ninety-three patients receiving Bisantrene on an every three week schedule developed an anaphylactoid reaction with a variety of symptoms. Most reactions occurred in patients who had multiple exposures to Bisantrene. Investigatiors utilizing Bisantrene in ongoing clinical trials should be aware of this life threatening toxicity.
Similar content being viewed by others
References
Von Hoff DD, Myers JW, Kuhn J, Sandbach JE, Pocelinko R, Clark G, Coltman CA Jr: Phase I clinical investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride (CL216942). Cancer Res 41:3118–3121, 1981
Spiegel RJ, Blum RH, Levin M, Pinto CA, Wernz JC, Speyer JL, Hoffman KS, Muggia FM: Phase I clinical trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Cancer Res 42:354–358, 1982
Myers JW, Von Hoff DD, Coltman CA Jr, Kuhn JG, Van Echo D, Rivkin S, Pocelinio R: Phase II evaluation of Bisantrene in patients with renal cell carcinoma. Cancer Treat Repts, 1982 (In press)
Alberts DS, Mackel C, Pocelinko R, Salmon SE: Phase I clinical investigation 9,10-Anthracenedicarboxaldehyde Bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone] Dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer Res 42:1170–1175, 1982
Yap BS, Yap HY, Blumenschein GR, Bedikian AY, Pocelinko R, Bodey GP: Phase I clinical evaluation of 9,10-An- thracenedicarboxy-aldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (Bisantrene). Cancer Treat Repts 66:1517–1520, 1982
Spiegel RJ, Levin M, Blum R, Speyer J, Wernz J, Pinto C, Muggia F: Phase II trial of daily × 5 Bisantrene in renal cell carcinoma. (Abstract) Proc Am Assoc Cancer Res 23:111, 1982
Scher H, Schwartz S, Yagoda A, Watson RC: Phase II trial of 9,10-Anthracenedicarboxaldehyde Bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride (CL216942) for metastatic hypernephroma. Proc Am Assoc Cancer Res 23:145, 1982
Perry MC, Forastiere AA, Richards F II, Weiss RB, Anbar D: Phase II trial of Anthracenedicarboxaldehyde (ADC) in advanced colorectal cancer: A CALGB study. (Abstract) Proc Am Soc Clin Oncol 1:102, 1982
Yap HY, Yap BS, Blumenschein GR, Barnes B, Schell F, Bodey GP: Bisantrene (CL216942), a promising new drug in the treatment of metastatic breast cancer. (Abstract) Proc Am Assoc Cancer Res 23:147, 1982
Gell PGH, Coombs RRA: In Clinical aspects of immunology. Blackwell Scientific Publications, Oxford, 1975
Weiss RB: Hypersensitivity Reactions to Cancer Chemotherapy. Sem Oncol 9:5–13, 1982
Herman EH, Young RSK: Acute cardiovascular alterations induced by low doses of Adriamycin, Rubidazone, and Daunorubicin in the anesthetized beagle dog. Cancer Treat Repts 63:1771–1779, 1979
Hatfield AK, Hardey L, Abderhalden RT: Chronic urticarial reactions caused by Doxorubicin-containing regimens. Cancer Treat Rep 65:353–354, 1981
Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K: Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study. Cancer Treat Repts 65:427–430, 1981
Alberts D: Personal communication, April 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Myers, J.W., Von Hoff, D.D., Kuhn, J.G. et al. Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs 1, 85–88 (1983). https://doi.org/10.1007/BF00180195
Issue Date:
DOI: https://doi.org/10.1007/BF00180195